{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:49:50Z","timestamp":1772786990988,"version":"3.50.1"},"reference-count":17,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Patiromer is a calcium (Ca)-potassium (K) exchange resin approved for the treatment of hyperkalemia. Disorders of Ca or acid base balance were not reported in pre-approval clinical trials. We present a case of a patient with chronic kidney disease (CKD) with an unusual picture of hypercalcemia, metabolic alkalosis and hypokalemia upon intensification of patiromer dosing. A 56-year-old white man with CKD stage 4 (baseline creatinine 2.8 mg\/dL) due to type 1 diabetes mellitus, proteinuria (1.5 g\/g) and persistently high serum potassium 5.9 mEq\/L attributed to type 4 renal tubular acidosis was evaluated in clinic. Due to high risk of CKD progression, patiromer 8.4 g daily, followed by 16.8 g daily was prescribed to enable renin angiotensin aldosterone system (RAAS) inhibitor. After 5 months of being on patiromer 16.8 g daily, routine laboratory tests revealed serum potassium 2.5 mEq\/L, serum calcium 12.8 mg\/dL and carbon dioxide 34 mEq\/L. Patiromer was discontinued and thorough investigation held was negative for other causes of hypercalcemia. Five days after patiromer discontinuation, serum calcium returned to normal. The role of secondary hyperparathyroidism in this case remains unclear. We, therefore recommend cautious vigilance of patients receiving patiromer and undergoing dose escalation.<\/jats:p>","DOI":"10.3390\/jcm10163756","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T10:24:17Z","timestamp":1629714257000},"page":"3756","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Rare Case of Patiromer Induced Hypercalcemia"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-6665","authenticated-orcid":false,"given":"Swetha Rani","family":"Kanduri","sequence":"first","affiliation":[{"name":"Department of Nephrology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA"},{"name":"Ochsner Clinical School, The University of Queensland, Brisbane, QLD 4072, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn J.","family":"Suchow","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos Q.","family":"Velez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Ochsner Clinic Foundation, New Orleans, LA 70121, USA"},{"name":"Ochsner Clinical School, The University of Queensland, Brisbane, QLD 4072, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1681\/ASN.2016121344","article-title":"How Dangerous Is Hyperkalemia?","volume":"28","author":"Montford","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dunlap, R.H., and Martinez, R. (2016). Total colectomy for colon perforation after kayexalate administration: A case report and literature review of a rare complication. J. Surg. Case Rep., 2016.","DOI":"10.1093\/jscr\/rjw167"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors","volume":"372","author":"Weir","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.kint.2020.06.042","article-title":"The potassium regulator patiromer affects serum and stool electrolytes in patients receiving hemodialysis","volume":"98","author":"Amdur","year":"2020","journal-title":"Kidney Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000451067","article-title":"Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis","volume":"44","author":"Bushinsky","year":"2016","journal-title":"Am. J. Nephrol."},{"key":"ref_8","unstructured":"US Food and Drug Administration (2021, August 19). Veltassa-Accessdata.fda.gov, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205739s000lbl.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/ki.2015.270","article-title":"Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia","volume":"88","author":"Bushinsky","year":"2015","journal-title":"Kidney Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.amjmed.2017.11.011","article-title":"Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors","volume":"131","author":"Weir","year":"2018","journal-title":"Am. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5414\/CNCS109782","article-title":"Case report: Patiromer-induced hypercalcemia","volume":"7","author":"Wiederkehr","year":"2019","journal-title":"Clin. Nephrol. Case Stud."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bhattarai, S., Pupillo, S., Dangol, G.M.S., and Sarac, E. (2019). Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect. Case Rep. Nephrol., 2019.","DOI":"10.1155\/2019\/3507407"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2215\/CJN.08910816","article-title":"Patiromer\u2014An Oral Calcium-Loaded Potassium Binder: Kalirrhea with Calciuresis","volume":"11","author":"Emmett","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2215\/CJN.04500418","article-title":"Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism","volume":"14","author":"Bushinsky","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2215\/CJN.01170216","article-title":"Effect of Patiromer on Urinary Ion Excretion in Healthy Adults","volume":"11","author":"Bushinsky","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"F485","DOI":"10.1152\/ajprenal.00608.2009","article-title":"Physiology and pathophysiology of the calcium-sensing receptor in the kidney","volume":"298","author":"Riccardi","year":"2010","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.kint.2015.11.018","article-title":"Treatment of hyperkalemia: Something old, something new","volume":"89","author":"Sterns","year":"2016","journal-title":"Kidney Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/16\/3756\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:49:57Z","timestamp":1760165397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/16\/3756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":17,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["jcm10163756"],"URL":"https:\/\/doi.org\/10.3390\/jcm10163756","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]}}}